{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["12"],"submitter":["Hu Y"],"funding":["National Natural Science Foundation of China"],"pubmed_abstract":["The combination of vonoprazan (VPZ) and amoxicillin (VA therapy) has been shown to achieve acceptable eradication rates for <i>Helicobacter pylori</i> (<i>H. pylori</i>). Herein, our aim was to explore the short-term effect of VA therapy on the gut microbiota and short-chain fatty acids (SCFAs) using human fecal samples. A total of 119 <i>H. pylori</i>-positive patients were randomized into low- or high-dose VA therapy (i.e., amoxicillin 1 g b.i.d. or t.i.d. and VPZ 20 mg b.i.d.) for 7 or 10 days. Thirteen <i>H. pylori</i>-negative patients served as controls. Fecal samples were collected from <i>H. pylori</i>-positive and <i>H. pylori</i>-negative patients. The gut microbiota and SCFAs were analyzed using 16S rRNA gene sequencing and gas chromatography-mass spectrometry, respectively. The gut microbiota in <i>H. pylori</i>-positive patients exhibited increased richness, diversity, and better evenness than matched patients. Fifty-three patients studied before and after <i>H. pylori</i> eradication were divided into low (L-VA) and high (H-VA) amoxicillin dose groups. The diversity and composition of the gut microbiota among L-VA patients exhibited no differences at the three time points. However, among H-VA patients, diversity was decreased, and the microbial composition was altered immediately after H-VA eradication but was restored by the confirmation time point. The decreased abundance of <i>Anaerostipes</i>, <i>Dialister</i>, and <i>Lachnospira</i> induced by H-VA was associated with altered SCFA levels. VA dual therapy for <i>H. pylori</i> eradication has minimal negative effects on gut microbiota and SCFAs."],"journal":["Frontiers in cellular and infection microbiology"],"pagination":["881968"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9201212"],"repository":["biostudies-literature"],"pubmed_title":["Altered Gut Microbiota and Short-Chain Fatty Acids After Vonoprazan-Amoxicillin Dual Therapy for <i>Helicobacter pylori</i> Eradication."],"pmcid":["PMC9201212"],"pubmed_authors":["He C","Hu Y","Zhu ZH","Xie Y","Lu NH","Zhu Y","Li NS","Peng C","Shu X","Xu X","Xie C","Ouyang YB"],"additional_accession":[]},"is_claimable":false,"name":"Altered Gut Microbiota and Short-Chain Fatty Acids After Vonoprazan-Amoxicillin Dual Therapy for <i>Helicobacter pylori</i> Eradication.","description":"The combination of vonoprazan (VPZ) and amoxicillin (VA therapy) has been shown to achieve acceptable eradication rates for <i>Helicobacter pylori</i> (<i>H. pylori</i>). Herein, our aim was to explore the short-term effect of VA therapy on the gut microbiota and short-chain fatty acids (SCFAs) using human fecal samples. A total of 119 <i>H. pylori</i>-positive patients were randomized into low- or high-dose VA therapy (i.e., amoxicillin 1 g b.i.d. or t.i.d. and VPZ 20 mg b.i.d.) for 7 or 10 days. Thirteen <i>H. pylori</i>-negative patients served as controls. Fecal samples were collected from <i>H. pylori</i>-positive and <i>H. pylori</i>-negative patients. The gut microbiota and SCFAs were analyzed using 16S rRNA gene sequencing and gas chromatography-mass spectrometry, respectively. The gut microbiota in <i>H. pylori</i>-positive patients exhibited increased richness, diversity, and better evenness than matched patients. Fifty-three patients studied before and after <i>H. pylori</i> eradication were divided into low (L-VA) and high (H-VA) amoxicillin dose groups. The diversity and composition of the gut microbiota among L-VA patients exhibited no differences at the three time points. However, among H-VA patients, diversity was decreased, and the microbial composition was altered immediately after H-VA eradication but was restored by the confirmation time point. The decreased abundance of <i>Anaerostipes</i>, <i>Dialister</i>, and <i>Lachnospira</i> induced by H-VA was associated with altered SCFA levels. VA dual therapy for <i>H. pylori</i> eradication has minimal negative effects on gut microbiota and SCFAs.","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2026-05-10T01:41:26.03Z","creation":"2025-02-19T02:57:53.492Z"},"accession":"S-EPMC9201212","cross_references":{"pubmed":["35719338"],"doi":["10.3389/fcimb.2022.881968"]}}